| News

Basel areas hold promise for investors

28.11.2019

Substantial efforts are underway in Basel to develop new areas and create space for people and companies. The efforts were welcomed by investors at the 17th Basler Investorengespräch.

The project Nordspitze exists for the area Dreispitz Nord (visualization: Herzog & de Meuron)

The 17th Basler Investorengespräch was held at the Kunstmuseum in Basel, according to the canton of Basel-Stadt. Executive Council President Elisabeth Ackermann welcomed 140 invited guests from across Switzerland who had sought to find out about the development of areas in Basel.

Occupying a total of 113 hectares, the areas under transformation are in central locations. In the coming 10 to 20 years, they will be developed with new living and working quarters in Basel’s effort to prepare for growth. The projects will create space for 20,000 new inhabitants and 30,000 jobs by 2035, confirmed Member of the Government of Basel-Stadt Hans-Peter Wessels in his speech.

Member of the Government Eva Herzog spoke about the research and administration site Areal Rosental Mitte, which is currently being transformed into a public quarter. There are plans to connect work with research and living space here, granting development opportunities to both companies in Basel and companies moving to the region. Lukas Ott, who heads cantonal and urban development in Basel-Stadt, also spoke about the variety of development across the areas. He said, Basel would do well to “develop its valuable transformation spaces gradually, flexibly and in a variety of ways”.

The event was rounded off by a panel about development in a rapidly changing market. Participants included cantonal architect Beat Aeberhard; the director of Immobilien Basel-Stadt, Rolf Borner; the head of development at SBB Immobilien, Susanne Zenker; and the CEO of Central Real Estate Basel AG, Andreas Fürst.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Novartis Campus
Basel Area Business & Innovation, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
Basel Area Business & Innovation, Switzerland Innovation Park

The innovation and enterprise campus GRID is filling up

Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Read More
Basel Area Business & Innovation, Innovation

Artidis ends successful study

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

Read More
Basel Area Business & Innovation, Innovation

Startup Academy celebrates anniversary

Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.

Read More
Basel Area Business & Innovation, Invest

Syngenta grows strongly and stays true to Basel

Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.

Read More
Basel Area Business & Innovation, Innovation

Tolremo raises additional funding

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Read More
Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
Basel Area Business & Innovation, Innovation

Polyneuron medication receives orphan drug status in the USA

The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.

Read More
Basel Area Business & Innovation, Innovation

BaseLaunch Applications open

BaseLaunch helps build therapeutic ventures to the point where they can raise a Series-A financing round or similar.

Read More
Basel Area Business & Innovation, Innovation

i4Challenge Applications open

The i4Challenge is an acceleration program for SME, startups and new projects focused on innovative solutions, new approaches and next-generation products or services for Industry 4.0.

Read More
Basel Area Business & Innovation, Invest

Ricola earns the trust of Switzerland

Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.